Association of Circulating Chemerin Levels and Arterial Stiffness

March 3, 2011 updated by: Korea University
Chemerin is a novel adipokine that might provide a link between chronic inflammation and obesity. Pulse wave velocity(PWV) is a useful method for examining arterial stiffness, meaning early-stage atherosclerosis. Therefore, in the present study, the investigators examined the relationship between circulating chemerin and arterial stiffness measured using PWV in obese persons.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Anticipated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Obese and age, gender matched non-obese group who underwent a medical health check in the Korea University Guro hospital

Description

Inclusion Criteria:

  • Self referred persons for visiting routine medical check in our clinic

Exclusion Criteria:

  • Malignancy
  • Severe renal or hepatic disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Obese group
Non- obese group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The difference of serum chemerin level between obese and non-obese groups
Time Frame: at the time of initial enrollment (4weeks)
serum chemerin levels of all participants were by determined by an enzyme-linked immunosorbent assay (ELISA) kit (Biovender Laboratory Medicine Inc., Modrice, Czech Republic)
at the time of initial enrollment (4weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The correlation of serum chemerin levels with arterial stiffness
Time Frame: at the time of enrollment (4 weeks)
Arterial stiffness was measure using a Colin Waveform Analyser (model BP-203RPE II; Colin, Komaki, Japan). It was expressed as branchial ankle pulswe wave velocity (baPWV)
at the time of enrollment (4 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Korea University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2011

Primary Completion (Anticipated)

March 1, 2011

Study Completion (Anticipated)

March 1, 2011

Study Registration Dates

First Submitted

February 10, 2011

First Submitted That Met QC Criteria

February 10, 2011

First Posted (Estimate)

February 11, 2011

Study Record Updates

Last Update Posted (Estimate)

March 4, 2011

Last Update Submitted That Met QC Criteria

March 3, 2011

Last Verified

January 1, 2011

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A102065-1011-1070100

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe